Jul 12, 2016
Lyon, France – BliNK Biomedical SAS (“BliNK”), a biopharmaceutical company focused on the discovery and development of novel ...Learn more
Valneva and BliNK Therapeutics Announce Launch of New Biotech Company in Innovative Antibody Discovery
European biotechnology company Valneva SE (“Valneva”) and UK company BliNK Therapeutics Ltd (“BliNK Therapeutics”) announced today the creation of a private company specialized in the discovery of innovative monoclonal antibodies to be headquartered in Lyon, France and to be named BliNK Biomedical SAS. The new company, which will benefit from the combination of two validated antibody discovery platforms, BliNK Therapeutics Ltd’s IVV and Valneva’s VIVA|Screen®, has already secured its first round of financing.
Dec 11, 2014
The creation of BliNK Biomedical SAS will give Valneva’s antibody business the necessary structure and prospects to expand into novel antibody ...Learn more